In the NewsPACIFICA-Study
This study is testing how well pacritinib works compared to other standard treatments in people...
New Free Online Course for Patient Advocates: “Interaction with Newly Diagnosed Patients”
The Blood Cancer Patient Advocates Academy has opened registration for its latest free online...
In Conversation with… The Steering Committee Members of the MPN Advocates Network
The MPN Advocates Network (MPN AN) is delighted to share a special vlogcast featuring its Steering...
WEBINAR: “Latest News from EHA 2024”
Dear members & friends, We are excited to announce a special webinar focusing on the latest...
Frontiers in MPNs
Dear members and friends, We would like to inform you that GSK is inviting the MPN Horizons...
Save the date for MPN Horizons 2024 Conference
Date: 6th -8th September 2024 Location: Warsaw, Poland Dear...
Complementary registration for EHA
Dear members and friends of MPN Advocates Network, The EHA (European Hematology Association) is...
Join us for “Looking at MPN and ASH 2023“ Webinar!
We are excited to invite you to our webinar “Looking at MPN and ASH 2023“. Our speaker Ronald...
MPN Horizons 2023 Conference videos & presentations now available
We are happy to announce that all videos and presentations of the MPN Horizons 2023 Conference are...
Dr. Ruben Mesa offers guidance to MPN Patients about the Coronavirus (Covid-19)
Dr. Ruben Mesa, Director, Mays Cancer Center, UT Health San Antonio, MD Anderson, offers guidance...
An MPN Update with Drs Ruben Mesa and Robyn Scherber
Dr. Ruben Mesa and Dr. Robyn Scherber hematologists from the Mays Cancer Center, home to UT Health...
Best of MPN News at ASH 2019
The MPN Advocates Network's Giora Sharf interviews Dr. Ruben Mesa from the UT Health San Antonio...
Patient Power Interviews Dr. Ruben Mesa about Fedratinib Approval
"BREAKING NEWS: The FDA has approved fedratinib as a new treatment option for myelofibrosis...